BOARD OF DIRECTORS

Show all
Patricia S. Andrews
Director

Ms. Andrews was named CEO of Boston Biomedical in April. She joined the company in 2013 and was most recently its Executive Vice President and Chief Operating Officer, where she prepared for launching the company’s first product, and guided the company’s pipeline development. Previously, she was Executive Vice President and Chief Commercial Officer at Incyte, leading commercial operations for that company’s launch of first-in-class, first-in-disease oncology product Jakafi®. Before that, she worked in leadership positions at Pfizer, where her final role was Vice President and General Manager of the US Oncology Business Unit, and at Marine Midland/HSBC, where she was Vice President in corporate finance. Ms. Andrews received her M.B.A. from the University of Michigan and her B.A. from Brown University.

M. James Barrett, Ph.D.
Chairman of the Board of Directors

Dr. Barrett joined venture capital firm New Enterprise Associates (NEA) in 2001 as a General Partner. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. Present board memberships in addition to GlycoMimetics include Clovis Oncology (NASDAQ:CLVS), PhaseBio Pharmaceuticals, Psyadon Pharmaceuticals, Roka Bioscience, and Senseonics. Prior to NEA, Dr. Barrett served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 - 2001). Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc. (1987 - 1995), President and CEO of Life Technologies (1985 - 1987), and President and CEO of Bethesda Research Labs (1982 - 1983). Prior to 1982, Dr. Barrett worked in various divisions of SmithKline. Dr. Barrett received a Ph.D. in Biochemistry at the University of Tennessee, his M.B.A. from the University of Santa Clara, and a B.S. in Chemistry from Boston College.

Mark A. Goldberg, M.D.
Director

Dr. Goldberg currently is a consultant to several biotechnology companies.  Previously he served as a medical and regulatory strategist for Synageva BioPharma Corp., from October 2014 until June 2015. Prior to that, he had served as Synageva’s Executive Vice President for Medical and Regulatory Strategy and as the Senior Vice President of Medical and Regulatory Affairs. Dr. Goldberg served in a variety of senior management positions at Genzyme Corporation from 1996 to July 2011, including most recently as Senior Vice President and Therapeutic Group Head for Oncology, Genetic and Neurodegenerative Diseases Clinical Development. Prior to working at Genzyme, he was a full-time staff physician at Brigham and Women’s Hospital and Dana Farber Cancer Institute, where he still holds appointments. He has also been an Associate Professor of Medicine at Harvard Medical School since 1996. Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. Dr. Goldberg currently also serves on the board of directors of ImmunoGen, Inc., Blueprint Medicines, Idera Pharaceuticals, and aTyr Pharma, all publicly traded companies.  Dr. Goldberg also served on the board of directors of Synageva from October 2008 to December 2011. Since 2010 Dr. Goldberg has served on the board of the New England Division of the American Cancer Society and is currently chair-elect.  He holds an A.B. from Harvard College and an M.D. from Harvard Medical School. 

Daniel M. Junius
Director

Mr. Junius has been a director of ImmunoGen, Inc., a development-stage biotechnology company since November 2008, a director of IDEXX Laboratories, Inc. since March 2014, and a director of GlycoMimetics, Inc. since March 2016. He was previously President and Chief Executive Officer of ImmunoGen from 2009 until his retirement in May 2016, President and Chief Operating Officer and Acting Chief Financial Officer from July 2008 to December 2008, Executive Vice President and Chief Financial Officer from 2006 to July 2008 and Senior Vice President and Chief Financial Officer from 2005 to 2006. Before joining ImmunoGen, Mr. Junius was Executive Vice President and Chief Financial Officer of New England Business Service, Inc. from 2002 until its acquisition by Deluxe Corporation in 2004 and Senior Vice President and Chief Financial Officer of New England Business Services from 1998 to 2002. Before joining New England Business Services, Mr. Junius was Vice President and Chief Financial Officer of Nashua Corporation from 1996 to 1998. Mr. Junius joined Nashua Corporation in 1984 and held various financial management positions of increasing responsibility before becoming Chief Financial Officer of Nashua Corporation in 1996. Mr. Junius holds an undergraduate degree in Political Science from Boston College and a Master’s in Management from Northwestern University’s Kellogg School of Management.

Rachel K. King
Chief Executive Officer

Mrs. King is co-founder and CEO of GlycoMimetics, Inc. (GMI).  Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms.  Mrs. King came to NEA after serving as a Senior Vice President of Novartis Corporation.  Before joining Novartis, Mrs. King spent ten years with Genetic Therapy, Inc. through the company’s early stage, initial public offering, and eventual sale to Novartis.  After the sale to Novartis, she was named CEO and ran the company as a wholly owned subsidiary of Novartis. Mrs. King also worked previously at ALZA Corporation in Palo Alto, California and at Bain and Company in Boston.  She received her B.A. degree from Dartmouth College and her M.B.A. from Harvard Business School.  Mrs. King is the past Chair of the Emerging Companies Governing Board and of the full Board of the Biotechnology Innovation Organization (“BIO”) and continues to serve on BIO’s Executive Committee.  She also served as Chair of the Maryland Life Sciences Advisory Board under former Governor Martin O’Malley, and now serves on the board of directors of Warp Drive Bio, a Third Rock Ventures-funded biotechnology company based in Cambridge, and of the University of Maryland BioPark.

    Scott Koenig M.D., Ph.D.
    Director

    Dr. Koenig has been President and Chief Executive Officer and a director of MacroGenics since September 2001 and was one of the company’s co-founders. Previously, Dr. Koenig served as Senior Vice President of Research at MedImmune, where he participated in the selection and maturation of their product pipeline. From 1984 to 1990, he worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Dr. Koenig currently serves as Chairman of the Board of Directors of Applied Genetic Technologies Corporation, and as a member of the Board of Directors of the Biotechnology Innovation Organization (BIO), the International Biomedical Research Alliance, and the co-chair of the Scientific Advisory Board of the Institute for Bioscience and Biotechnology Research (IBBR) at the University of Maryland. Dr. Koenig received his A.B. and Ph.D. from Cornell University and his M.D. from the University of Texas Health Science Center in Houston.

     

    John Magnani, Ph.D.
    Senior Vice-President, Research and Chief Scientific Officer

    Dr. Magnani is co-founder and CSO of GlycoMimetics, Inc (GMI). Prior to co-founding GMI, Dr. Magnani founded and led the predecessor company, GlycoTech Corporation as its President and CEO. Previously, he helped co-found the U.S. subsidiary of BioCarb and became its international Vice President of Research. Dr. Magnani received his Ph.D. from Princeton University and then joined the Laboratory of Biological Pharmacology of the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases, (NIADDK) of the National Institutes of Health (NIH). He remained at the NIH for ten years, finally serving as a tenured Research Chemist. Dr. Magnani is an expert in glycobiology having discovered and characterized many carbohydrate tumor antigens, such as the FDA-approved cancer diagnostic, CA19-9, and developed fundamental technology for the identification of functional carbohydrate epitopes. Dr. Magnani is the discoverer of Sialyl Lea and its functions. He was the first to identify the binding domain to the selectins common to both Sialyl Lea and Sialyl Lex and used this information to develop potent selectin antagonists as drug candidates now in clinical trials. He is the recipient of the 2015 President’s Innovation Award from the Society of Glycobiology and has authored over 100 scientific publications and is an inventor on over 30 issued patents. 

      Timothy R. Pearson
      Director

      Mr. Pearson currently holds the position of Chief Financial Officer for TESARO, Inc., an oncology-focused biopharmaceutical company. Most recently before his TESARO appointment, he held the position of Chief Financial Officer, Executive Vice President and Treasurer at Catalyst Health Solutions, a publicly held pharmacy benefit manager with over $5 billion in revenues. Mr. Pearson led the company’s financial activities, including performance management, investor relations, SEC compliance, capital strategy and planning, until the company was acquired by SXC Health Solutions (now Catamaran Corporation) in 2012.  Prior to joining Catalyst Health Solutions, Mr. Pearson served as Chief Financial Officer and Executive Vice President of MedImmune, the global biologics business for AstraZeneca PLC, where he had functional responsibility for finance, information technology, strategic planning and governance, and was a member of MedImmune’s Executive Team.  Mr. Pearson joined MedImmune in 1998 and prior to the acquisition by AstraZeneca and his promotion to CFO in 2007, was Vice President of Finance and Treasurer with responsibility for treasury, corporate finance, tax, risk management, Sarbanes-Oxley compliance, internal audit and equity plan administration. Prior to MedImmune, Mr. Pearson held various financial roles of increasing responsibility at Integrated Health Services, CIGNA Insurance and First National Bank of Maryland.  Mr. Pearson, a Certified Public Accountant, holds dual Bachelor of Science degrees in Business Administration from the University of Delaware and Accounting from the University of Maryland University College, as well as a Master of Science degree in Finance from Loyola University.